임상 검체에서 분리된 세균에 대한 Cefcapene의 시험관내 항균력
In vitro Antimicrobial Activity of Cefcapene against Clinical Isolates
2
조회
0
다운로드
1
인용
0
참고문헌
초록
목 적 : Cefcapene은 새로운 경구 cephem계 광범위항생제로 Staphylococcus aureus와 Streptococi를 포함한 그람양성균, 그람음성균에 광범위한 항균력을 나타낸다고 보고되고 있다. 본 연구에서는 임상에서 분리된 균주에 대하여 cefcapene과 다른 cephalosporin항생제의 시험관내 항균력을 조사하였다.재료 및 방법 : 2000년부터 2003년까지 서울아산병원에서 분리된 450균주를 대상으로 하여 cefcapene과 다른 cephalosporin 항생제의 시험관내 항균력을 검사하였다. 항생제 최소억제농도는 NCCLS기준을 따랐다.결 과 : 다른 cephalosporin항생제(cefaclor, cefpodoxime, cefixime)들과 비교하여 cefcapene은 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, methicillin감수성 Staphylococcus aureus에서 낮은 MIC분포를 나타내었다. Cefcapene은 Enterobacteriaceae에 대해서는 다양한 항균력을 보여주었다.결 론:Cefcapene은 지역사회 호흡기감염의 흔한 원인균과 methicillin 감수성 S. aureus에 탁월한 시험관내 감수성을 보였다. 따라서 cefcapene은 지역사회 폐렴과 methicillin 감수성 S. aureus감염증의 치료를 위한 경구항생제로 유용할 것으로 생각된다.
Abstract
Background : Cefcapene pivoxil hydrochloride is a new oral cephem which has a broad-spectrum activity with expanded potency against Gram-positive bacteria, including Staphylococcus aureus and Streptococcus, as well as Gram-negative bacteria. In this study, we examined the in vitro activity of cefcapene against recently isolated clinical specimens from patients in a tertiary hospital. Materials and Methods : We tested the in vitro antimicrobial activities of cefcapene and other cephalosporins against 450 clinical isolates from of patients in Asan Medical Center. Minimal inhibitory concentrations (MICs) were determined by agar dilution method according to the recommendations of National Committee for Clinical Laboratory Standards. Results : Compared with other cephalosporins (cefaclor, cefpodoxime, and cefixime), cefcapene had lower MIC distributions for Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and methicillin-susceptible S. aureus. Cefcapene had variable activity against Enterobateriaceae. Conclusion : Cefcapene had excellent in vitro antimicrobial activities against common typical bacterial respiratory tract pathogens and methicillin-susceptible S. aureus. Cefcapene appears to be a promising agent for treatment of community-acquired respiratory tract infections and infections caused by methicillin-susceptible S. aureus.
참고문헌 (15)
- "Clinical efficacy of cefpodoxime in respiratory tract infection", pp.23~7 (2002)
- "Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia", 112, pp.406~15 (1997)
- "In Vitro Activities of Amoxicillin-Sulbactam against Major Clinical Isolates of Bacteria", 20, pp.203~12 (2002)
- "Study of the absorption of cefcapene pivoxil in patients with infectious disease and soft stool or diarrhea", pp.75~82 (2003)
- "Comparative antimicrobial susceptibility of respiratory tract pathogens", 1, pp.3~10 (2004)
- "antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections", pp.49~59 (2002)
- "Efficacy of azithromycin clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice", 48, pp.425~30 (2001)
- "NNational Committee for Clinical Laboratory Standards 2004:Performance standards for antimicrobial susceptibility testing, 14th informational supplement.", pp.14~ (2004)
- "Yamaguchi K:Cefcapene inactivates chromosome- encoded class C beta-lactamases.", pp.207~10 (2002)
- "a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong", 23, pp.44~51
- "Emergence and spread of antimicrobial resistance of Streptococcus pneumoniae in Korea", 39, pp.546~53 (1998)
- "High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia", pp.2101~7 (2004)
- "In Vitro Activities of Amoxicillin-Sulbactam against Major Clinical Isolates of Bacteria", 20, pp.203~12 (2002)
- "Comparative antimicrobial susceptibility of respiratory tract pathogens", pp.3~10 (2004)
- "antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections", pp.49~59 (2002)